Prosight Management, LP Janux Therapeutics, Inc. Transaction History
Prosight Management, LP
- $369 Million
- Q2 2025
A detailed history of Prosight Management, LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 853,904 shares of JANX stock, worth $22.6 Million. This represents 5.34% of its overall portfolio holdings.
Number of Shares
853,904
Previous 689,901
23.77%
Holding current value
$22.6 Million
Previous $18.6 Million
5.89%
% of portfolio
5.34%
Previous 6.63%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
56.4MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$296 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$118 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$77.3 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$66.9 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$64 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.1B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...